Investigations into the fate of inhaled salmon calcitonin at the respiratory epithelial barrier

Pharmaceutical Research

Volumn 29, Issue 1, 2012, Pages 332-341

  Baginski, Leonie ^a,b   Tewes, Frederic ^a   Buckley, Stephen T ^a   Healy, Anne Marie ^a   Bakowsky, Udo ^b   Ehrhardt, Carsten ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

In vitro cell culture; Inhaled biopharmaceuticals; Osteoporosis; Peptidases; Proteinases

Indexed keywords

BACITRACIN; CHYMOTRYPSIN; LEUKOCYTE ELASTASE; SALCATONIN; TRYPSIN; CALCITONIN;

ARTICLE; CELL FREE SYSTEM; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG STABILITY; DRUG TRANSPORT; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME LOCALIZATION; EPITHELIUM CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; PERMEABILITY BARRIER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY EPITHELIUM; SUPERNATANT; CELL LINE; CELL STRAIN CACO 2; INHALATIONAL DRUG ADMINISTRATION; LUNG GAS EXCHANGE; METABOLISM; OSTEOPOROSIS; RESPIRATORY TRACT MUCOSA; TRANSPORT AT THE CELLULAR LEVEL;

ADMINISTRATION, INHALATION; BIOLOGICAL TRANSPORT; BLOOD-AIR BARRIER; CACO-2 CELLS; CALCITONIN; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHYMOTRYPSIN; HUMANS; LEUKOCYTE ELASTASE; OSTEOPOROSIS; RESPIRATORY MUCOSA; TRYPSIN;

EID: 84860595588     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0553-z     Document Type: Article

References (40)

1. Stevenson CL. Advances in peptide pharmaceuticals. Curr Pharm Biotechnol. 2009;10(1):122-37.
2. Patton JS, Brain JD, Davies LA, Fiegel J, Gumbleton M, Kim KJ, et al. The particle has landed-characterizing the fate of inhaled pharmaceuticals. J Aerosol Med Pulm Drug Deliv. 2010;23 Suppl 2:S71-87.
3. Patton JS, Platz RM. (D) Routes of delivery: Case studies: (2) Pulmonary delivery of peptides and proteins for systemic action. Adv Drug Deliv Rev. 1992;8(2-3):179-96.
4. Woodley J. Enzymatic barriers for GI peptide and protein delivery. Crit Rev Ther Drug Carrier Syst. 1994;11(2-3):61-95.
5. Baginski L, Tachon G, Falson G, Patton J, Bakowsky U, Ehrhardt C. Reverse transcription polymerase chain reaction (RT-PCR) analysis of proteolytic enzymes in cultures of human respiratory epithelial cells. J Aerosol Med Pulm Drug Deliv. 2011;24(2):89-101.
6. Patton JS. Mechanisms of macromolecule absorption by the lungs. Adv Drug Deliv Rev. 1996;19(1):3-36. (Pubitemid 26167852)
7. Dershwitz M, Walsh J, Morishige R, Connors P, Rubsamen R, Shafer S, et al. Pharmacokinetics and pharmacodynamics of inhaled versus intravenous morphine in healthy volunteers. Anesthesiology. 2000;93(3):619-28.
8. Patton J, Byron P. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6(1):67-74. (Pubitemid 46020287)
9. Bernkop-Schnürch A, Kast C, Guggi D. Permeation enhancing polymers in oral delivery of hydrophilic macromolecules: thiomer/ GSH systems. J Control Release. 2003;93(2):95-103. (Pubitemid 37421352)
10. Lang S, Staudenmann W, James P, Manz H, Kessler R, Galli B, et al. Proteolysis of human calcitonin in excised bovine nasal mucosa: elucidation of the metabolic pathway by liquid secondary ionization mass spectrometry (LSIMS) and matrix assisted laser desorption ionization mass spectrometry (MALDI). Pharm Res. 1996;13(11):1679-85.
11. Dohi M, Nishibe Y, Makino Y, Suzuki Y, editors. Enzymatic barrier to nasal delivery of salmon calcitonin in rabbits. Proceedings of the International Symposium Control on Relative Society. Kyoto, Japan: 1993.
12. Guggi D, Bernkop-Schnürch A. In vitro evaluation of polymeric excipients protecting calcitonin against degradation by intestinal serine proteases. Int J Pharm. 2003;252(1-2):187-96. (Pubitemid 36126627)
13. Reid P, Marsden M, Cunningham G, Haslett C, Sallenave J. Human neutrophil elastase regulates the expression and secretion of elafin (elastase-specific inhibitor) in type II alveolar epithelial cells. FEBS Lett. 1999;457(1):33-7. (Pubitemid 29387404)
14. Fogh J, Trempe G. New human tumor cell lines. In: Fogh J, editor. Human tumor cells in vitro. New York: Plenum; 1975. p. 115-59.
15. Giard D, Aaronson S, Todaro G, Arnstein P, Kersey J, Dosik H, et al. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Canc Inst. 1973;51(5):1417-23.
16. Sporty J, Horálková L, Ehrhardt C. In vitro cell culture models for the assessment of pulmonary drug disposition. Expert Opin Drug Metab Toxicol. 2008;4(4):333-45. (Pubitemid 351728510)
17. Schwert G, Takenaka Y. A spectrophotometric determination of trypsin and chymotrypsin. Biochim Biophys Acta. 1955;16(4):570-5.
18. Cotter T, Robinson G. Purification and characterisation of an 'elastase-like' enzyme from rabbit polymorphonuclear leucocytes. Biochim Biophys Acta. 1980;615(2):414-25. (Pubitemid 11191808)
19. Visser L, Blout E. The use of p-nitrophenyl N-tertbutyloxycarbonyl- L-alaninate as substrate for elastase. Biochim Biophys Acta. 1972;268(1):257-60.
20. Shah R, Khan M. Protection of salmon calcitonin breakdown with serine proteases by various ovomucoid species for oral drug delivery. J Pharm Sci. 2004;93(2):392-406. (Pubitemid 38174260)
21. Kobayashi S, Kondo S, Juni K. Study on pulmonary delivery of salmon calcitonin in rats: effects of protease inhibitors and absorption enhancers. Pharm Res. 1994;11(9):1239-43. (Pubitemid 24287400)
22. Bernkop-Schnürch A. The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins. J Control Release. 1998;52(1-2):1-16. (Pubitemid 28123168)
23. Yamahara H, Lehr C, Lee V, Kim K. Fate of insulin during transit across rat alveolar epithelial cell monolayers. Eur J Pharm Biopharm. 1994;40:294-8. (Pubitemid 24342914)
24. Forbes B, Wilson CG, Gumbleton M. Temporal dependence of ectopeptidase expression in alveolar epithelial cell culture: implications for study of peptide absorption. Int J Pharm. 1999;180(2):225-34. (Pubitemid 29238206)
25. Kobayashi S, Kondo S, Juni K. Pulmonary delivery of salmon calcitonin dry powders containing absorption enhancers in rats. Pharm Res. 1996;13(1):80-3. (Pubitemid 26076300)
26. Kawabata K, Hagio T, Matsuoka S. The role of neutrophil elastase in acute lung injury. Eur J Pharmacol. 2002;451(1):1-10. (Pubitemid 35251839)
27. Sun Z, Yang P. Role of imbalance between neutrophil elastase and alpha 1-antitrypsin in cancer development and progression. Lancet Oncol. 2004;5(3):182-90. (Pubitemid 38262851)
28. Amelinckx A, Whitney P, Santos N, Lascano J, Salathe M, Conner G, et al. Regulation and anti-elastase activity of locally produced alpha-1-antitrypsin by well differentiated normal airway epithelial cells: a comparison with SLPI. Am J Respir Crit Care Med. 2010;181:A4158.
29. Wall DA, Lanutti AT. High levels of exopeptidase activity are present in rat and canine bronchoalveolar lavage fluid. Int J Pharm. 1993;97:171-81. (Pubitemid 23242378)
30. Lang S, Rothen-Rutishauser B, Perriard JC, Schmidt MC, Merkle HP. Permeation and pathways of human calcitonin (hCT) across excised bovine nasal mucosa. Peptides. 1998;19(3):599-607. (Pubitemid 28161175)
31. Gaudiano MC, Colone M, Bombelli C, Chistolini P, Valvo L, Diociaiuti M. Early stages of salmon calcitonin aggregation: effect induced by ageing and oxidation processes in water and in the presence of model membranes. Biochim Biophys Acta. 2005;1750(2):134-45. (Pubitemid 40835860)
32. Youn Y, Jung J, Oh S, Yoo S, Lee K. Improved intestinal delivery of salmon calcitonin by Lys18-amine specific PEGylation: stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic efficacy. J Control Release. 2006;114(3):334-42. (Pubitemid 44310815)
33. Song K, Chung S, Shim C. Enhanced intestinal absorption of salmon calcitonin (sCT) from proliposomes containing bile salts. J Control Release. 2005;106(3):298-308. (Pubitemid 41187439)
34. Torres-Lugo M, García M, Record R, Peppas NA. pH-Sensitive hydrogels as gastrointestinal tract absorption enhancers: transport mechanisms of salmon calcitonin and other model molecules using the Caco-2 cell model. Biotechnol Prog. 2002;18(3):612-6. (Pubitemid 34623236)
35. Tréhin R, Krauss U, Beck-Sickinger A, Merkle H, Nielsen H. Cellular uptake but low permeation of human calcitonin-derived cell penetrating peptides and Tat(47-57) through well-differentiated epithelial models. Pharm Res. 2004;21(7):1248-56. (Pubitemid 38954211)
36. Patton JS, Trinchero P, Platz RM. Bioavailability of pulmonary delivered peptides and proteins: [alpha]-interferon, calcitonins and parathyroid hormones. J Control Release. 1994;28(1-3):79-85.
37. Clark A, Kuo MC, Newman S, Hirst P, Pitcairn G, Pickford M. A comparison of the pulmonary bioavailability of powder and liquid aerosol formulations of salmon calcitonin. Pharm Res. 2008;25 (7):1583-90.
38. Lewiecki EM. Emerging drugs for postmenopausal osteoporosis. Expert Opin Emerg Drugs. 2009;14(1):129-44.
39. Youn YS, Kwon MJ, Na DH, Chae SY, Lee S, Lee KC. Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection. J Control Release. 2008;125(1):68-75. (Pubitemid 350198681)
40. Lombry C, Edwards DA, Préat V, Vanbever R. Alveolar macrophages are a primary barrier to pulmonary absorption of macromolecules. Am J Physiol Lung Cell Mol Physiol. 2004;286(5):L1002-8. (Pubitemid 38508811)